Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Jönsson, Simon ^a   Lundberg, Anna ^a   Kälvegren, Hanna ^a   Bergström, Ida ^a   Szymanowski, Aleksander ^a   Jonasson, Lena ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERLEUKIN 8; MESSENGER RNA; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CELL ISOLATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME BLOOD LEVEL; ENZYME RELEASE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; STABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; ANGIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LEUKOCYTES; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEUTROPHILS; PEROXIDASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

ANGINA;

EID: 79955765430     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019340     Document Type: Article

References (44)

1. Galis ZS, Khatri JJ, (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 90 (3): 251-262.
2. Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PRF, et al. (2004) Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 110 (3): 337-343.
3. Bäck M, Ketelhuth DFJ, Agewall S, (2010) Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 52 (5): 410-428.
4. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC, (2004) Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 110 (13): 1747-1753.
5. Jones GT, Kay IP, Chu JWS, Wilkins GT, Phillips LV, et al. (2006) Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis. Arterioscler Thromb Vasc Biol 26 (7): e121-125.
6. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, et al. (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (12): 1579-1585.
7. Boekholdt SM, Peters RJ, Hack CE, Day NE, Luben R, et al. (2004) IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: The EPIC-norfolk prospective population study. Arterioscler Thromb Vasc Biol 24 (8): 1503-1508.
8. Jefferis BJ, Whincup P, Welsh P, Wannamethee G, Rumley A, et al. (2010) Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 208 (2): 557-563.
9. Tuomainen AM, Jauhiainen M, Kovanen PT, Metso J, Paju S, et al. (2008) Aggregatibacter actinomycetemcomitans induces MMP-9 expression and proatherogenic lipoprotein profile in apoE-deficient mice. Microb Pathog 44 (2): 111-117.
10. Tuomainen AM, Nyyssonen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, et al. (2007) Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 27 (12): 2722-2728.
11. Momiyama Y, Ohmori R, Tanaka N, Kato R, Taniguchi H, et al. (2010) High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis 209 (1): 206-210.
12. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, et al. (1998) Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (2): 368-372.
13. Nanni S, Melandri G, Hanemaaijer R, Cervi V, Tomasi L, et al. (2007) Matrix metalloproteinases in premature coronary atherosclerosis: Influence of inhibitors, inflammation, and genetic polymorphisms. Translational Research 149 (3): 137-144.
14. Brunner S, Kim J, Methe H, (2010) Relation of matrix metalloproteinase-9/Tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Am J Cardiol 105 (4): 429-434.
15. Noji Y, Kajinami K, Kawashiri M, Todo Y, Horita T, et al. (2001) Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clinical Chemistry and Laboratory Medicine 39 (5): 380-384.
16. Tayebjee MH, Lip GYH, Tan KT, Patel JV, Hughes EA, et al. (2005) Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 96 (3): 339-345.
17. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, et al. (2001) Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141 (2): 211-217.
18. Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, Kolb H, (2006) Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 26 (1): 194-199.
19. Szymanowski A, Nijm J, Kristenson M, Jonasson L, (2011) Elevated levels of circulating matrix metalloproteinase-9 are associated with a dysregulated cortisol rhythm-A case-control study of coronary artery disease. Psychoneuroendocrinology In Press, Corrected Proof.
20. Tayebjee MH, Lip GY, Tan KT, MacFadyen RJ, (2006) Abnormal circulating neutrophil linked matrix metalloproteinase-9 in stable coronary artery disease. Thromb Haemost 95 (1): 202-204.
21. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE, (2007) Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 40 (1-2): 119-123.
22. Mannello F, (2008) Serum or plasma samples?: The "cinderella" role of blood collection procedures preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol 28 (4): 611-614.
23. Hasty KA, Hibbs MS, Kang AH, Mainardi CL, (1986) Secreted forms of human neutrophil collagenase. J Biol Chem 261 (12): 5645-5650.
24. Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, et al. (2003) Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 126 (12): 2738-2749.
25. Fang L, Du XJ, Gao XM, Dart AM, (2010) Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction. Clin Sci (Lond) 119 (4): 175-183.
26. Sapienza P, di Marzo L, Borrelli V, Sterpetti AV, Mingoli A, et al. (2005) Metalloproteinases and their inhibitors are markers of plaque instability. Surgery 137 (3): 355-363.
27. Fiotti N, Altamura N, Orlando C, Simi L, Reimers B, et al. (2008) Metalloproteinases-2,-9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int J Cardiol 127 (3): 350-357.
28. Newby AC, (2008) Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 28 (12): 2108-2114.
29. Campeau L, (1976) Letter: Grading of angina pectoris. Circulation 54 (3): 522-523.
30. Boyum A, (1968) Isolation of mononuclear cells and granulocytes from human blood. isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97: 77-89.
31. Borregaard N, Cowland JB, (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89 (10): 3503-3521.
32. Pugin J, Widmer MC, Kossodo S, Liang CM, Preas HL II, et al. (1999) Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 20 (3): 458-464.
33. Claesson R, Johansson A, Belibasakis G, Hanstrom L, Kalfas S, (2002) Release and activation of matrix metalloproteinase 8 from human neutrophils triggered by the leukotoxin of actinobacillus actinomycetemcomitans. J Periodontal Res 37 (5): 353-359.
34. Nijm J, Wikby A, Tompa A, Olsson AG, Jonasson L, (2005) Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol 95 (4): 452-456.
35. Särndahl E, Bergström I, Brodin VP, Nijm J, Setterud HL, et al. (2007) Neutrophil activation status in stable coronary artery disease. PLoS ONE 2 (10): e1056.
36. Paulsson J, Dadfar E, Held C, Jacobson SH, Lundahl J, (2007) Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis 192 (2): 328-334.
37. Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, et al. (2004) Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 110 (21): 3349-3354.
38. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, et al. (2009) Effects of low-dose aspirin on acute inflammatory responses in humans. The Journal of Immunology 183 (3): 2089-2096.
39. Negrotto S, Malaver E, Alvarez ME, Pacienza N, D'Atri LP, et al. (2006) Aspirin and salicylate suppress polymorphonuclear apoptosis delay mediated by proinflammatory stimuli. Journal of Pharmacology and Experimental Therapeutics 319 (2): 972-979.
40. Ardans JA, Economou AP, Martinson JM Jr, Zhou M, Wahl LM, (2002) Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and-9 by activated monocytes. J Leukoc Biol 71 (6): 1012-1018.
41. Johnatty R, Taub D, Reeder S, Turcovski-Corrales S, Cottam D, et al. (1997) Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 158 (5): 2327-2333.
42. Houard X, Ollivier V, Louedec L, Michel J, Bäck M, (2009) Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. The FASEB Journal 23 (5): 1376-1383.
43. Brew K, Dinakarpandian D, Nagase H, (2000) Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochimica Et Biophysica Acta (BBA)- Protein Structure and Molecular Enzymology 1477 (1-2): 267-283.
44. Aznaouridis K, Vlachopoulos C, Dima I, Vasiliadou C, Ioakeimidis N, et al. (2007) Divergent associations of tissue inhibitors of metalloproteinases-1 and-2 with the prothrombotic/fibrinolytic state. Atherosclerosis 195 (1): 212-215.